Home Search
viaskin peanut - search results
If you're not happy with the results, please do another search
Viaskin Milk Results Shows Potential for Treatment of Milk Allergy in Children
95.5% of the participants completed treatment, with most adverse effects being mild or moderate reactions at the application site.
FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial to Commence
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Skin Patch Immunotherapy Determined Safe and Effective in Toddlers With Peanut Allergy
According to research presented at this year's #ACAAI22 meeting.
DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and Eggs, to Lay...
The company announced they would be laying off 200 employees in Q1.
Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies
FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut...
The AAFA addresses concerns
regarding the Final Evidence Report released by the ICER.
ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not Yet Demonstrate That...
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Asthma and Allergy Foundation of America Elevates Patient Voice in ICER Review of New...
Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
Joint Statement on Peanut Allergy Therapy Review
Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.
Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for Peanut Allergy
An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.